Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 4:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 5,507 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo once daily Clear all
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Ecosystem Nourishment for Gut Restoration After Fecal Transplantation

NCT07826793
View directory record Official record
Conditions
Aging
Interventions
Fecal Microbiota Transplant Capsules, Microbiome Rejuvenating Diet, Placebo Fecal Microbiota Transplantation
Drug · Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 4:47 PM EDT
Terminated Phase 3 Interventional Results available

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

NCT03629249
View directory record Official record
Conditions
Asthma
Interventions
Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 84 Years
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 28, 2026, 4:47 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

NCT05815485
View directory record Official record
Conditions
COVID-19
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Perimenopausal Estrogen Replacement Therapy Study

NCT01308814
View directory record Official record
Conditions
Perimenopause, Menopause, Depression
Interventions
Estradiol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
172 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

NCT03941548
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
5
States / cities
Centennial, Colorado • Tampa, Florida • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

NCT02675426
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
57
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

NCT00605215
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo, Avonex®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

NCT02344290
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Pitavastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
40 Years to 75 Years
Enrollment
7,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
91
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 28, 2026, 4:47 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 28, 2026, 4:47 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

NCT07678346
View directory record Official record
Conditions
Systemic Inflammation (hsCRP), Healthy Aging, Vitality, Healthy Adult Participants
Interventions
Apple Extract, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraland USA, Inc.
Industry
Eligibility
45 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 28, 2026, 4:47 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Decentralized Study to Evaluate a Dietary Supplement for Episodes of Mild Acute Stress in Healthy People

NCT07511088
View directory record Official record
Conditions
Situational Anxiety
Interventions
Botanical extract for anxiety, Placebo capsule
Dietary Supplement
Lead sponsor
PLT Health Solutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2 Interventional

A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease

NCT01320527
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Nutriceutical formulation, Placebo
Dietary Supplement · Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Naples, Florida • Baltimore, Maryland • Ayer, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 4 Interventional

A Study of Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Lap. Prostatectomy

NCT01661166
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Fesoterodine, Placebo oral tablet
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
30 Years to 90 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 28, 2026, 4:47 PM EDT
Recruiting Early Phase 1 Interventional

Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain

NCT07260656
View directory record Official record
Conditions
Diabetic Neuropathies, Painful, Diabetic Foot, Diabetic Peripheral Neuropathy
Interventions
Capsaicin Palmitate, Placebo
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Results available

A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

NCT00853151
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2428757, TT223, Placebo for LY2428757, Placebo for TT223
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
26
States / cities
Birmingham, Alabama • Anaheim, California • Artesia, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

NCT02654002
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Cilofexor, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dapagliflozin In Alzheimer's Disease

NCT03801642
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Jeff Burns, MD
Other
Eligibility
50 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair

NCT01920594
View directory record Official record
Conditions
Surgical Procedures
Interventions
GSK1278863, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib in Parkinson's Disease

NCT03205488
View directory record Official record
Conditions
Parkinson Disease
Interventions
Cohort 1:Nilotinib Oral Capsules (150mg or 300mg), Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1), Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 79 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Sun City, Arizona • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

NCT01974570
View directory record Official record
Conditions
Prehypertension
Interventions
Marealis refined peptide concentrate, Placebo
Dietary Supplement
Lead sponsor
KGK Science Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 28, 2026, 4:47 PM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 4:47 PM EDT
Withdrawn Phase 3 Interventional

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

NCT02974322
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
136
States / cities
Litchfield Park, Arizona • Mesa, Arizona • Phoenix, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 28, 2026, 4:47 PM EDT
Completed Phase 3 Interventional Results available

PREPARE (A5361s) Ancillary Study of REPRIEVE (A5332)

NCT03070223
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pitavastatin, Placebos
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 75 Years
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Oct 28, 2026, 4:47 PM EDT